Clinical trials: Cholangiocarcinoma Cancer
Cholangiocarcinoma
Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients
This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the consistency and accuracy of patient-derived organoid model of cholangiocarcinoma to predict the…
- Trial name
- NCT05634694
- Testing
- No interventions.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cholangiocarcinoma, Biliary Tract Cancer
Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
This is a single center, nonrandom, open-label study aiming to evluate the efficacy and safety of lenvatinib for patients with pretreated advanced biliary tract cancer.
- Conditions
- Cholangiocarcinoma, Biliary Tract Cancer, Targeted Therapy
- Trial name
- LENABC (NCT04656249)
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking Union Medical College Hospital
Intrahepatic Cholangiocarcinoma (Icc), Liver Injury
Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed.
- Trial name
- NCT07760038
- Testing
- Phycocyanin, Maltodextrin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy
A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST
This project aims to conduct a prospective, multicenter, randomized controlled clinical trial. The study plans to enroll 270 patients with locally advanced iCCA who have successfully undergone GOLP conversion therapy.
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST, GOLP Regimen
- Trial name
- NCT07208526
- Testing
- GOLP regimen, Surgery, TDTP-RECIST
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Cancer, Hepatocellular Cancer
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol 1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine +…
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- NCT05451043
- Testing
- Durvalumab, Gemcitabine, Nab paclitaxel
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- AHS Cancer Control Alberta
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Intrahepatic Cholangiocarcinoma
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
1. Phase of Development: II 2. Patient Population: Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma 3. Estimated Number of Patients: 34 patients 4.
- Trial name
- NCT04546828
- Testing
- Gemcitabine, Cisplatin, and Nab-Paclitaxe
- Sponsor
- Samsung Medical Center
Hilar Cholangiocarcinoma
Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma
This is a multi-center, randomized, controlled, open-label, phase IIa clinical study.The study will observe the efficacy and safety of Deuteporfin photodynamic therapy in addition to stenting compared to stenting alone in…
- Trial name
- NCT02955771
- Testing
- PDT-Deuteporfin（6 hour), PDT-Deuteporfin（9 hour), stenting
- Where
- 4 sites in China
- Volunteers
- 7 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Intrahepatic Cholangiocarcinoma
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
This is a single-center, open-label, phase II clinical trial designed to evaluate the efficacy and safety of chidamide in combination with chemotherapy and immunotherapy as a first-line treatment for patients with advanced…
- Trial name
- NCT07570849
- Testing
- Chidamide, Gemcitabine, cisplatin, immune checkpoint inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining…
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Resectable, Cholangiocarcinoma; Liver
- Trial name
- LyMIC (NCT06381648)
- Testing
- LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
- Where
- 4 sites in United States, Japan
- Volunteers
- 230 people
- Sponsor
- City of Hope Medical Center
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
- Conditions
- Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02990481
- Testing
- TRK-950
- Where
- 3 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- Toray Industries, Inc
Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases, Liver Malignant Tumors
- Trial name
- TIKET (NCT06487663)
- Testing
- TACE with ICI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Title: A Study of Cadonilimab Combined with Capecitabine After Surgery for Mixed Type Liver Cancer This is a phase II clinical trial.
- Trial name
- NCT07243951
- Testing
- Cadonilimab, Capecitabine
- Volunteers
- 75 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholangiocarcinoma
Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma
The purpose of this study is to assess efficacy and tolerance of intra-hepatic administration of Yttrium 90-labelled microsphere (Theraspheres®, Nordion) in association with intravenous chemotherapy with Gemcitabin and Cisplatin…
- Trial name
- MispheC (NCT01912053)
- Testing
- Therasphere® in association with Gemcitabine and Cisplatin
- Where
- 7 sites in France
- Volunteers
- 41 people
- Sponsor
- Center Eugene Marquis
Cholangiocarcinoma, Chondrosarcoma
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma, that harbor an IDH1 mutation.
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Other Advanced Solid Tumors
- Trial name
- NCT02073994
- Testing
- AG-120
- Where
- 12 sites in United States, France
- Volunteers
- 174 people
- Sponsor
- Institut de Recherches Internationales Servier
Advanced Solid Tumours
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
This study is to evaluate the preliminary efficacy and safety of RXC004 monotherapy and in combination with pembrolizumab in advanced solid tumours that have progressed following SoC treatment.
- Trial name
- KEYNOTE-E86 (NCT04907851)
- Testing
- RXC004, Denosumab, pembrolizumab
- Where
- 13 sites in Australia, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Redx Pharma Ltd
Liver Cancer, Hepatocellular Carcinoma
Proton Therapy and Bevacizumab for Primary Liver Tumors
Primary Objectives: 1. To evaluate the safety of the treatment of patients with technically or medically inoperable hepatocellular carcinoma and cholangiocarcinoma with proton therapy and concurrent bevacizumab biotherapy. 2.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT00426829
- Testing
- Bevacizumab, Proton Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Cholangiocarcinoma
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
The purpose of this project is to evaluate the role of gadoxetate (Eovist®) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma.
- Trial name
- NCT01673802
- Testing
- CT scan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Alabama at Birmingham
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery
RATIONALE: Biliary stenting is the placement of a tube in the bile ducts to keep a blocked area open. Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells.
- Trial name
- Photostent-02 (NCT00513539)
- Testing
- porfimer sodium, biliary stenting
- Where
- 4 sites in United Kingdom
- Volunteers
- 92 people
- Sponsor
- University College, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.